ARDT Stock Forecast 2025-2026
Distance to ARDT Price Targets
ARDT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ardent Health (ARDT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ARDT and similar high-potential opportunities.
Latest ARDT Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ARDT has a bullish consensus with a median price target of $21.00 (ranging from $17.00 to $24.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $13.11, the median forecast implies a 60.2% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Gillmor at Keybanc, projecting a 83.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARDT Analyst Ratings
ARDT Price Target Range
Latest ARDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $21.00 |
| Feb 27, 2025 | Stephens & Co. | Raj Kumar | Overweight | Reiterates | $22.00 |
| Jan 21, 2025 | Morgan Stanley | Craig Hettenbach | Overweight | Maintains | $22.00 |
| Jan 6, 2025 | Truist Securities | Buy | Maintains | $0.00 | |
| Nov 14, 2024 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $23.00 |
| Nov 12, 2024 | Leerink Partners | Whit Mayo | Outperform | Maintains | $25.00 |
| Nov 6, 2024 | B of A Securities | Kevin Fischbeck | Neutral | Downgrade | $19.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Overweight | Initiates | $24.00 |
| Sep 19, 2024 | Stephens & Co. | Scott Fidel | Overweight | Reiterates | $24.00 |
| Aug 16, 2024 | Truist Securities | David Macdonald | Buy | Reiterates | $22.00 |
| Aug 16, 2024 | Loop Capital | Timothy Greaves | Buy | Maintains | $21.00 |
| Aug 15, 2024 | Stephens & Co. | Scott Fidel | Overweight | Reiterates | $24.00 |
| Aug 12, 2024 | Morgan Stanley | Craig Hettenbach | Overweight | Initiates | $27.00 |
| Aug 12, 2024 | Citigroup | Buy | Initiates | $21.00 | |
| Aug 12, 2024 | JP Morgan | Lisa Gill | Neutral | Initiates | $18.00 |
| Aug 12, 2024 | Leerink Partners | Whit Mayo | Outperform | Initiates | $23.00 |
| Aug 12, 2024 | Loop Capital | Timothy Greaves | Buy | Initiates | $18.00 |
| Aug 12, 2024 | Mizuho | Ann Hynes | Outperform | Initiates | $20.00 |
| Aug 12, 2024 | B of A Securities | Kevin Fischbeck | Buy | Initiates | $22.00 |
| Aug 12, 2024 | RBC Capital | Ben Hendrix | Outperform | Initiates | $23.00 |
Ardent Health Partners Inc. (ARDT) Competitors
The following stocks are similar to Ardent Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ardent Health Partners Inc. (ARDT) Financial Data
Ardent Health Partners Inc. has a market capitalization of $1.87B with a P/E ratio of 8.3x. The company generates $5.97B in trailing twelve-month revenue with a 3.5% profit margin.
Revenue growth is +19.3% quarter-over-quarter, while maintaining an operating margin of +9.8% and return on equity of +23.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ardent Health Partners Inc. (ARDT) Business Model
About Ardent Health Partners Inc.
Delivers comprehensive healthcare services across the U.S.
The company operates a network of acute care hospitals, outpatient campuses, and specialty facilities. It generates revenue through the provision of a wide range of healthcare services, including emergency, intensive, surgical, and diagnostic imaging care, catering to diverse community needs.
Headquartered in Nashville, Tennessee, Ardent Health Partners is focused on enhancing patient care and improving community health standards. Its integrated approach and commitment to quality care contribute to the resilience and accessibility of healthcare systems.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
19,200
CEO
Mr. Martin J. Bonick FACHE, M.H.A.
Country
United States
IPO Year
2024
Website
www.ardenthealth.comArdent Health Partners Inc. (ARDT) Latest News & Analysis
Ardent Health Partners, Inc. (NYSE: ARDT) reported its fourth quarter and full year results for 2024, comparing them to the same periods in the previous year. Further details are available in the press release.
Ardent Health's Q4 2024 results can indicate growth potential and financial health, influencing stock performance and investor sentiment in the healthcare sector.
Ardent Health (NYSE: ARDT) will participate in the Leerink Partners Global Healthcare Conference on March 10, 2025, with a fireside chat at 8 a.m. ET in Miami, Florida.
Ardent Health's participation in key investor conferences may signal growth opportunities and strategic direction, potentially influencing investor sentiment and stock performance.
TruLite Health has expanded its leadership team and strengthened its AI capabilities to address clinical bias in healthcare, appointing Walter D. Conwell, MD, MBA, as president.
TruLite Health's leadership expansion and focus on AI capabilities signal growth potential and increased market relevance, which may drive investor confidence and impact stock performance.
Ardent Health Announces Fourth Quarter and Full Year 2024 Results Conference Call and Webcast Date
1 month agoArdent Health (NYSE: ARDT) will release its Q4 and full year 2024 results on February 26, 2025, after market close, with a conference call on February 27 at 9:00 a.m. ET.
Ardent Health's upcoming financial results and conference call will provide insights into performance and strategic direction, influencing investor sentiment and stock valuation.
Q4 is expected to see rising patient volumes and technological advancements benefiting healthcare companies like AMGN, COR, HUM, and ARDT, which may outperform.
Increased patient volumes and tech advances suggest strong earnings potential for healthcare firms like AMGN, COR, HUM, and ARDT, signaling growth opportunities for investors.
U.S. stock futures rose this morning, with Dow futures up over 150 points on Tuesday.
Rising U.S. stock futures indicate positive market sentiment, potentially leading to gains in equities and influencing trading strategies and investment decisions.
Frequently Asked Questions About ARDT Stock
What is Ardent Health Partners Inc.'s (ARDT) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Ardent Health Partners Inc. (ARDT) has a median price target of $21.00. The highest price target is $24.00 and the lowest is $17.00.
Is ARDT stock a good investment in 2025?
According to current analyst ratings, ARDT has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARDT stock?
Wall Street analysts predict ARDT stock could reach $21.00 in the next 12 months. This represents a 60.2% increase from the current price of $13.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ardent Health Partners Inc.'s business model?
The company operates a network of acute care hospitals, outpatient campuses, and specialty facilities. It generates revenue through the provision of a wide range of healthcare services, including emergency, intensive, surgical, and diagnostic imaging care, catering to diverse community needs.
What is the highest forecasted price for ARDT Ardent Health Partners Inc.?
The highest price target for ARDT is $24.00 from Matthew Gillmor at Keybanc, which represents a 83.1% increase from the current price of $13.11.
What is the lowest forecasted price for ARDT Ardent Health Partners Inc.?
The lowest price target for ARDT is $17.00 from at , which represents a 29.7% increase from the current price of $13.11.
What is the overall ARDT consensus from analysts for Ardent Health Partners Inc.?
The overall analyst consensus for ARDT is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are ARDT stock price projections?
Stock price projections, including those for Ardent Health Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
